IN2014MN01936A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01936A
IN2014MN01936A IN1936MUN2014A IN2014MN01936A IN 2014MN01936 A IN2014MN01936 A IN 2014MN01936A IN 1936MUN2014 A IN1936MUN2014 A IN 1936MUN2014A IN 2014MN01936 A IN2014MN01936 A IN 2014MN01936A
Authority
IN
India
Prior art keywords
cancer
level
getting
risk
female subject
Prior art date
Application number
Other languages
English (en)
Inventor
Andreas Bergmann
Olle Melander
Original Assignee
Sphingotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh
Publication of IN2014MN01936A publication Critical patent/IN2014MN01936A/en

Links

Classifications

    • G01N33/57585—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/575—
    • G01N33/57515—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
IN1936MUN2014 2012-03-08 2013-03-08 IN2014MN01936A (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261608346P 2012-03-08 2012-03-08
EP12158679 2012-03-08
EP12165054 2012-04-20
PCT/EP2013/054800 WO2013132089A2 (en) 2012-03-08 2013-03-08 A method for predicting the risk of getting cancer or diagnosing cancer in a female subject

Publications (1)

Publication Number Publication Date
IN2014MN01936A true IN2014MN01936A (pl) 2015-07-10

Family

ID=49117445

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1936MUN2014 IN2014MN01936A (pl) 2012-03-08 2013-03-08

Country Status (7)

Country Link
US (2) US20150031144A1 (pl)
EP (1) EP2823313B1 (pl)
JP (1) JP6290795B2 (pl)
CN (1) CN103308689B (pl)
IN (1) IN2014MN01936A (pl)
RU (1) RU2642623C2 (pl)
WO (1) WO2013132089A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502973A (ja) 2013-12-30 2017-01-26 オンコプレフェント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を予防する方法において使用するためのニューロキニン−１受容体アンタゴニスト
CN104237535B (zh) * 2014-09-30 2016-02-10 天津市泌尿外科研究所 神经降压素在诊断去势抵抗性前列腺癌神经内分泌化亚型和判断预后中的应用
EP3002589A1 (en) 2014-10-01 2016-04-06 sphingotec GmbH A method for stratifying a female subject for hormone replacement therapy
CA2977494A1 (en) * 2015-02-27 2016-05-06 Sphingotec Gmbh A method for predicting the risk of obesity in a subject
KR102618553B1 (ko) * 2022-08-31 2023-12-27 숙명여자대학교산학협력단 당뇨병 환자의 유방암 발병 예측 및 유방암 환자의 예후 예측용 바이오마커

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
MXPA04001804A (es) 2001-08-30 2005-03-07 Biorexis Pharmaceutical Corp Proteinas de fusion de transferrina modificada.
DK2298278T3 (en) 2002-06-07 2016-02-01 Dyax Corp Prevention and reduction of blood loss and inflammatory response
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20050233393A1 (en) * 2004-02-27 2005-10-20 Wynne-Edwards Katherine E Dynamic hormone index as a biomarker for disease
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
CA2580881A1 (en) 2004-09-21 2006-03-30 Nascacell Technologies Ag Use of microproteins as tryptase inhibitors
DE102005003687A1 (de) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
WO2007093373A2 (en) * 2006-02-14 2007-08-23 Università Degli Studi Di Siena Branched multimeric peptides for tumor diagnosis and therapy
US8449864B2 (en) * 2006-10-20 2013-05-28 The Board Of Trustees Of The Leland Stanford Junior University Neurotensin as a marker and therapeutic target for sepsis
JPWO2009044561A1 (ja) * 2007-10-03 2011-02-03 静岡県 抗ｐｒｏＮＴ／ＮＭＮモノクローナル抗体
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
CA2742241C (en) 2008-11-03 2019-12-10 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
ES2538002T3 (es) * 2009-01-07 2015-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama
CN102869678A (zh) 2009-08-27 2013-01-09 科瓦根股份公司 Il-17结合化合物及其医药用途
WO2011073214A2 (en) 2009-12-14 2011-06-23 Scil Proteins Gmbh A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
RS58839B1 (sr) 2010-06-08 2019-07-31 Pieris Pharmaceuticals Gmbh Muteini lipokalina u suzama koji vezuju il-4 r alfa
CN103308670B (zh) * 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
TR201809183T4 (tr) * 2012-10-02 2018-07-23 Sphingotec Gmbh Bir dişi sujede kansere yakalanma riskini tahmin etmek için bir usul.

Also Published As

Publication number Publication date
EP2823313B1 (en) 2019-09-18
JP2015512047A (ja) 2015-04-23
US20150031144A1 (en) 2015-01-29
CN103308689A (zh) 2013-09-18
US20210109102A1 (en) 2021-04-15
EP2823313A2 (en) 2015-01-14
WO2013132089A4 (en) 2014-04-10
RU2014140432A (ru) 2016-04-27
RU2642623C2 (ru) 2018-01-25
JP6290795B2 (ja) 2018-03-07
WO2013132089A2 (en) 2013-09-12
CN103308689B (zh) 2017-04-12
WO2013132089A3 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
IL270864A (en) Identification of biomarkers on vesicles for diagnosis and prognosis of diseases and disorders
IN2013CN01129A (pl)
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2013084002A3 (en) Method for detecting nucleosome adducts
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
WO2014028884A3 (en) Cancer diagnostics using biomarkers
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
MX382266B (es) Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama.
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
IN2014MN01936A (pl)
SG10201808585TA (en) Compositions and methods related to diagnosis of prostate cancer
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
SMT201900474T1 (it) Microrna biomarcatori per identificare il rischio di e/o per diagnosticare tumore ai polmoni
HK1220253A1 (zh) 诊断前列腺癌症的方法
IN2014MN01940A (pl)
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2017015700A (es) Igfbp3 y sus usos.
IN2015DN01646A (pl)
FR2996192B1 (fr) Procede de determination de l'etat d'usure d'une piece et d'information d'un client
MA40636A (fr) Procédés pour détecter le cancer de la prostate
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
GB2510539A (en) Biomarkers of cancer
PL3289096T3 (pl) Sposób prognozowania i/lub diagnozowania choroby na podstawie próbki tkanki tłuszczowej
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama